{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T23:12:57Z","timestamp":1789773177603,"version":"4.0.1"},"reference-count":20,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Among biological agents for the treatment of atopic dermatitis (AD), dupilumab is a front-runner. Although many studies have been conducted on the real-world use of dupilumab, the sample size is often small and data is primarily on Western people. Therefore, we investigated the efficacy and safety of dupilumab in patients with moderate-to-severe AD in Korea. All patients with moderate-to-severe AD treated with dupilumab from September 2018 to June 2019 in this institution were included and analyzed by medical records. They were evaluated using the Eczema Area and Severity Index (EASI), Numerical Rating Scale (NRS), Patient Oriented Eczema Measure (POEM), and Dermatology Quality of Life Index (DLQI), respectively on admission, after two weeks (only EASI and NRS) and after 16 weeks. Laboratory tests were measured before and 16 weeks after treatment. A total of 101 patients were included. All efficacy tools showed a significant decrease after 16 weeks; EASI 77.4%, NRS 70.0%, POEM 60.7%, and DLQI 65.0%. EASI was characterized by a marked improvement of 51.5% in just two weeks. The treatment response was not significantly different according to the interval of treatment. Elevated Lactate Dehydrogenase (LDH) at 16 weeks was associated with poor treatment response. Moreover, a high eosinophil count was related to a lower change in EASI and POEM. In the correlation analysis, EASI was not correlated to DLQI before treatment. For changes after 16 weeks, POEM showed the highest correlation with DLQI. (R = 0.66, p &lt; 0.001) In the additional analysis for factors affecting treatment response, the female gender was associated with good treatment response. (odds ratio = 5.4, p = 0.04) Adverse events from treatment included facial erythema (9.9%) and conjunctivitis (5.0%). Overall, it was confirmed that the efficacy of dupilumab in the real-world is similar to that of the existing clinical trials. We suggest that POEM is a useful tool for identifying the quality of life. The female gender was associated with a good treatment response. Both an elevated LDH and a high eosinophil count could be a therapeutic biomarker. Further research will be needed for a long-term period.<\/jats:p>","DOI":"10.3390\/jcm9061982","type":"journal-article","created":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T10:54:59Z","timestamp":1592996099000},"page":"1982","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":49,"title":["Retrospective Study of Dupilumab Treatment for Moderate to Severe Atopic Dermatitis in Korea: Efficacy and Safety of Dupilumab in Real-World Practice"],"prefix":"10.3390","volume":"9","author":[{"given":"Dong Hyek","family":"Jang","sequence":"first","affiliation":[{"name":"Department of Dermatology, National Medical Center, Seoul 04564, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8764-7995","authenticated-orcid":false,"given":"Seok Jae","family":"Heo","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Computing, Yonsei University Graduate School, Seoul 03722, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Jung","family":"Jung","sequence":"additional","affiliation":[{"name":"Department of Dermatology, National Medical Center, Seoul 04564, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Yeon","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Dermatology, National Medical Center, Seoul 04564, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong Jun","family":"Seo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Chung-Ang University Hospital, Seoul 06973, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6766-9978","authenticated-orcid":false,"given":"Jiyoung","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Dermatology, National Medical Center, Seoul 04564, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.det.2017.02.005","article-title":"The Role of Interleukins 4 and\/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis","volume":"35","author":"Silverberg","year":"2017","journal-title":"Dermatol. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 Trials of Dupilumab versus Placebo in Atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N. Eng. J. Med."},{"key":"ref_4","first-page":"418","article-title":"Effectiveness of dupilumab treatment in 95 patients with atopic dermatitis: Daily practice data","volume":"182","author":"Bosma","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1111\/jdv.15609","article-title":"Treatment of atopic dermatitis with dupilumab: Experience from a tertiary referral centre","volume":"33","author":"Olesen","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_6","first-page":"21","article-title":"Dupilumab: Short-term effectiveness and security in real clinical practice \u2013 A retrospective multicentric study","volume":"33","year":"2019","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1111\/bjd.17629","article-title":"Effect of dupilumab on atopic manifestations in patients treated for atopic dermatitis in real-life practice","volume":"180","author":"Tauber","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaad.2003.08.003","article-title":"Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)\/American Academy of Dermatology Association \u201cAdministrative Regulations for Evidence Based Clinical Practice Guidelines\u201d","volume":"50","author":"Hanifin","year":"2004","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1034\/j.1600-0625.2001.100102.x","article-title":"The eczema area and severity index (EASI): Assessment of reliability in atopic dermatitis","volume":"10","author":"Hanifin","year":"2001","journal-title":"Exp. Dermatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1111\/bjd.18390","article-title":"Validation of the Peak Pruritus Numerical Rating Scale","volume":"181","author":"Yosipovitch","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/bjd.15179","article-title":"Patient-Oriented Eczema Measure (POEM), a core instrument to measure symptoms in clinical trials: A Harmonising Outcome Measures for Eczema (HOME) statement","volume":"176","author":"Spuls","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","article-title":"Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: A placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAF\u00c9)","volume":"178","author":"Smith","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"ref_15","first-page":"202","article-title":"The Atopic March: Progression from Atopic Dermatitis to Allergic Rhinitis and Asthma","volume":"5","author":"Selene","year":"2014","journal-title":"J. Clin. Cell Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/1346-8138.14540","article-title":"Survey of disease awareness, treatment behavior and treatment satisfaction in patients with atopic dermatitis in Korea: A multicenter study","volume":"45","author":"Jung","year":"2018","journal-title":"J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1159\/000113150","article-title":"Relationship between Clinical Response to Therapy and Health-Related Quality of Life Outcomes in Patients with Moderate to Severe Plaque Psoriasis","volume":"216","author":"Revicki","year":"2008","journal-title":"Dermatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaad.2019.02.053","article-title":"Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort","volume":"81","author":"Faiz","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_19","unstructured":"Dalia, Y., and Marchese Johnson, S. (2018). Case Report: First Reported Case of Facial Rash after Dupilumab Therapy, Practical Dermatology."},{"key":"ref_20","first-page":"79","article-title":"Dupilumab side effect in a patient with atopic dermatitis: A case report study","volume":"13","author":"Albader","year":"2019","journal-title":"Biologics"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/6\/1982\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:42:27Z","timestamp":1760175747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/6\/1982"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":20,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["jcm9061982"],"URL":"https:\/\/doi.org\/10.3390\/jcm9061982","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]}}}